Aspirin for COVID-19: real-time meta analysis of 79 studies

Significantly lower risk is seen for mortality and progression. 28 studies from 26 independent teams in 11 countries show significant benefit.

Meta analysis using the most serious outcome reported shows 8% [2‑13%] lower risk. Early treatment is more effective than late treatment.

Control Aspirin

Studies to date do not show a significant benefit for mechanical ventilation and ICU admission. Benefit may be more likely without coadministered anticoagulants. The RECOVERY RCT shows 4% [-4‑11%] lower mortality for all patients, however when restricting to non-LMWH patients there was 17% [-4‑34%] improvement, comparable with the mortality results of all studies, 8% [2‑14%], and the 16% improvement in the REMAP-CAP RCT.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

4 other meta analyses show significant improvements with aspirin for mortality1-3, mechanical ventilation1, and progression4.

4 meta analyses show significant improvements with aspirin for mortality1-3, mechanical ventilation1, and progression4.